LV10577B - Use of omeprazole as an antimicrobal agent - Google Patents

Use of omeprazole as an antimicrobal agent Download PDF

Info

Publication number: LV10577B
Authority: LV; Latvia
Prior art keywords: omeprazole; salt; methoxy; pct; capsules
Prior art date: 1989-02-09

Application number

LVP-94-169A

Other languages

English (en)

Latvian (lv)

Other versions

LV10577A (lv

Inventor

Tomoi Masaaki

Ikeda Yoshifumi

Yokota Yoshiko

Original Assignee

Haessle Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-09

Filing date

1994-08-30

Publication date

1995-10-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12300238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10577(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-08-30 Application filed by Haessle Ab filed Critical Haessle Ab

1995-04-20 Publication of LV10577A publication Critical patent/LV10577A/xx

1995-10-20 Publication of LV10577B publication Critical patent/LV10577B/en

Links

SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims abstract description 20
229960000381 omeprazole Drugs 0.000 title description 17
230000003377 anti-microbal effect Effects 0.000 title 1
150000003839 salts Chemical class 0.000 claims abstract description 20
238000011282 treatment Methods 0.000 claims abstract description 8
206010051226 Campylobacter infection Diseases 0.000 claims description 2
208000035473 Communicable disease Diseases 0.000 abstract description 4
241000590002 Helicobacter pylori Species 0.000 abstract description 3
239000004480 active ingredient Substances 0.000 description 13
230000000845 anti-microbial effect Effects 0.000 description 11
239000002775 capsule Substances 0.000 description 10
239000008188 pellet Substances 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
-1 4-methoxy-3,5-dimethyl-2-pyridinyl Chemical group 0.000 description 7
239000000203 mixture Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
239000004615 ingredient Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
239000004599 antimicrobial Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000007787 solid Substances 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
241000283073 Equus caballus Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000000034 method Methods 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920000945 Amylopectin Polymers 0.000 description 2
241000589562 Brucella Species 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229940063517 omeprazole sodium Drugs 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000589876 Campylobacter Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
241000009328 Perro Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010042566 Superinfection Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
CDZHZLQKNAKKEC-UHFFFAOYSA-N [bis(hydroxymethylamino)methylamino]methanol Chemical class OCNC(NCO)NCO CDZHZLQKNAKKEC-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical class C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000003912 environmental pollution Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002597 lactoses Chemical class 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical class C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LVP-94-169A 1989-02-09 1994-08-30 Use of omeprazole as an antimicrobal agent LV10577B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP1030311A JP2694361B2 (ja)	1989-02-09	1989-02-09	抗菌剤
PCT/SE1990/000070 WO1990009175A1 (en)	1989-02-09	1990-02-02	Use of omeprazole as an antimicrobial agent

Publications (2)

Publication Number	Publication Date
LV10577A LV10577A (lv)	1995-04-20
LV10577B true LV10577B (en)	1995-10-20

Family

ID=12300238

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-94-169A LV10577B (en)	1989-02-09	1994-08-30	Use of omeprazole as an antimicrobal agent

Country Status (19)

Country	Link
US (1)	US5093342A (de)
EP (1)	EP0414847B1 (de)
JP (1)	JP2694361B2 (de)
KR (1)	KR0140236B1 (de)
AT (1)	ATE94063T1 (de)
AU (1)	AU626641B2 (de)
CA (1)	CA2025668C (de)
CY (1)	CY1909A (de)
DE (1)	DE69003207T2 (de)
DK (1)	DK0414847T3 (de)
ES (1)	ES2058892T3 (de)
HK (1)	HK52196A (de)
HU (1)	HU205253B (de)
IE (1)	IE65814B1 (de)
IL (1)	IL93263A0 (de)
LV (1)	LV10577B (de)
MY (1)	MY111737A (de)
PH (1)	PH26787A (de)
WO (1)	WO1990009175A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69014141T2 (de) *	1989-02-10	1995-05-24	Takeda Chemical Industries Ltd	Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel.
GB9018603D0 (en) *	1990-08-24	1990-10-10	Smith Kline French Lab	Compositions
WO1992004898A1 (de) *	1990-09-14	1992-04-02	Byk Gulden Lomberg Chemische Fabrik Gmbh	Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachten erkrankungen
IL105155A (en) *	1992-04-24	1999-05-09	Astra Ab	Combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
US5504082A (en) *	1992-06-01	1996-04-02	Yoshitomi Pharmaceutical Industries, Ltd.	Pyridine compound and pharmaceutical compostions
EP0673246A1 (de) *	1992-12-10	1995-09-27	Byk Gulden Lomberg Chemische Fabrik GmbH	Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
US6426085B1 (en)	1994-05-02	2002-07-30	Josman Laboratories Inc.	Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en)	1994-05-02	1998-11-10	Josman Laboratories, Inc.	Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) *	1994-05-02	2005-06-07	Josman Laboratories, Inc.	Topical oral dosage forms containing bismuth compounds
US6372784B1 (en)	1995-02-07	2002-04-16	Josman Laboratories, Inc.	Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
AU4596796A (en) *	1995-02-07	1996-08-27	Narayan Krishnarao Athanikar	Concomitant treatment with bismuth and antibacterials
US6379651B1 (en)	1995-02-07	2002-04-30	Josman Laboratories	Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US5708017A (en) *	1995-04-04	1998-01-13	Merck & Co., Inc.	Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US5840737A (en)	1996-01-04	1998-11-24	The Curators Of The University Of Missouri	Omeprazole solution and method for using same
US6645988B2 (en) *	1996-01-04	2003-11-11	Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en)	1996-01-04	2002-12-03	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) *	1996-01-04	2004-03-02	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and methods of using same
SI9700186B (sl)	1997-07-14	2006-10-31	Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.	Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6096340A (en) *	1997-11-14	2000-08-01	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6174548B1 (en)	1998-08-28	2001-01-16	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
ATE500815T1 (de) *	1997-12-08	2011-03-15	Dietrich Rango	Neue suppositoriumsform mit säureempfindlichem wirkstoff
US6861448B2 (en) *	1998-01-14	2005-03-01	Virtual Drug Development, Inc.	NAD synthetase inhibitors and uses thereof
IL137229A0 (en)	1998-01-14	2001-07-24	Uab Research Foundation	Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6733778B1 (en) *	1999-08-27	2004-05-11	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6245913B1 (en)	1999-06-30	2001-06-12	Wockhardt Europe Limited	Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6312712B1 (en)	1999-08-26	2001-11-06	Robert R. Whittle	Method of improving bioavailability
US6369087B1 (en) *	1999-08-26	2002-04-09	Robert R. Whittle	Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en)	1999-08-26	2001-11-06	Robert R. Whittle	Pharmaceutical unit dosage form
US6268385B1 (en)	1999-08-26	2001-07-31	Robert R. Whittle	Dry blend pharmaceutical formulations
US6262085B1 (en)	1999-08-26	2001-07-17	Robert R. Whittle	Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en)	1999-08-26	2001-12-04	Robert R. Whittle	Dry blend pharmaceutical unit dosage form
US6316020B1 (en)	1999-08-26	2001-11-13	Robert R. Whittle	Pharmaceutical formulations
US6262086B1 (en)	1999-08-26	2001-07-17	Robert R. Whittle	Pharmaceutical unit dosage form
US6780880B1 (en)	1999-08-26	2004-08-24	Robert R. Whittle	FT-Raman spectroscopic measurement
US6787342B2 (en)	2000-02-16	2004-09-07	Merial Limited	Paste formulations
SE0002476D0 (sv)	2000-06-30	2000-06-30	Astrazeneca Ab	New compounds
CA2450073C (en)	2001-07-25	2017-08-29	Biomarin Pharmaceutical Inc.	Compositions and methods for modulating blood-brain barrier transport
WO2003063840A2 (en) *	2002-01-25	2003-08-07	Santarus, Inc.	Transmucosal delivery of proton pump inhibitors
TWI367759B (en) *	2003-02-20	2012-07-11	Santarus Inc	A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004257864A1 (en) *	2003-07-18	2005-01-27	Santarus, Inc.	Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CA2531564C (en) *	2003-07-18	2016-01-19	Santarus, Inc.	Pharmaceutical composition for inhibiting acid secretion
US20070292498A1 (en) *	2003-11-05	2007-12-20	Warren Hall	Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8815916B2 (en)	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP2671508B1 (de)	2005-04-28	2020-09-16	Proteus Digital Health, Inc.	Pharma-Informatiksystem
DK2003130T3 (da)	2006-03-10	2011-12-12	Arigen Pharmaceuticals Inc	Nyt pyridinderivat med anti-helicobacter pylori-aktivitet
JP2010503710A (ja)	2006-09-18	2010-02-04	ラプトールファーマシューティカルインコーポレイテッド	受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
CA2665226C (en)	2006-10-05	2014-05-13	Santarus, Inc.	Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) *	2007-10-05	2009-04-09	Santarus, Inc.	Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en)	2006-10-27	2008-05-01	The Curators Of The University Of Missouri	Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
ES2390611T3 (es)	2006-12-18	2012-11-14	Arigen Pharmaceuticals, Inc.	Agente de erradicación de Helicobacter pylori que tiene actividad inhibidora sobre la secreción de ácido gástrico
ES2919563T3 (es)	2009-02-20	2022-07-27	Enhanx Biopharm Inc	Sistema de administración de medicamentos a base de glutatión
EP2420500A4 (de)	2009-04-09	2012-09-05	Arigen Pharmaceuticals Inc	Pyridinthioderivat sowie pharmazeutische zusammensetzung damit und mit anti-helidobacter-pylori-wirkung
KR20180114970A (ko)	2009-05-06	2018-10-19	라보라토리 스킨 케어, 인크.	활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US8992897B2 (en)	2010-01-06	2015-03-31	Elc Management Llc	Skin lightening compositions
US8722026B2 (en) *	2010-01-06	2014-05-13	Elc Management, Llc	Skin lightening compositions
US20120077778A1 (en)	2010-09-29	2012-03-29	Andrea Bourdelais	Ladder-Frame Polyether Conjugates
KR101628474B1 (ko) *	2014-08-27	2016-06-08	경북대학교 산학협력단	오메프라졸을 유효성분으로 포함하는 피부 미백용 화장료 조성물
JP2025532389A (ja)	2022-10-04	2025-09-29	ザビリュク，アルセニー	大動脈弁の石灰化の抑制

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
US4359465A (en) *	1980-07-28	1982-11-16	The Upjohn Company	Methods for treating gastrointestinal inflammation
SE8301182D0 (sv) *	1983-03-04	1983-03-04	Haessle Ab	Novel compounds
KR890701580A (ko) *	1987-10-30	1989-12-21	앤더스 베딘	골(骨)손실에 관련된 질병 치료용 2-피리디닐메틸(술피닐 또는 티오) 벤즈이미다졸

1989
- 1989-02-09 JP JP1030311A patent/JP2694361B2/ja not_active Expired - Lifetime
1990
- 1990-02-02 US US07/572,951 patent/US5093342A/en not_active Expired - Fee Related
- 1990-02-02 HU HU901539A patent/HU205253B/hu not_active IP Right Cessation
- 1990-02-02 ES ES90902854T patent/ES2058892T3/es not_active Expired - Lifetime
- 1990-02-02 DE DE90902854T patent/DE69003207T2/de not_active Expired - Fee Related
- 1990-02-02 DK DK90902854.0T patent/DK0414847T3/da active
- 1990-02-02 AT AT90902854T patent/ATE94063T1/de not_active IP Right Cessation
- 1990-02-02 AU AU50381/90A patent/AU626641B2/en not_active Ceased
- 1990-02-02 CY CY190990A patent/CY1909A/xx unknown
- 1990-02-02 WO PCT/SE1990/000070 patent/WO1990009175A1/en not_active Ceased
- 1990-02-02 IL IL93263A patent/IL93263A0/xx not_active IP Right Cessation
- 1990-02-02 EP EP90902854A patent/EP0414847B1/de not_active Expired - Lifetime
- 1990-02-02 CA CA002025668A patent/CA2025668C/en not_active Expired - Lifetime
- 1990-02-02 KR KR1019900702221A patent/KR0140236B1/ko not_active Expired - Fee Related
- 1990-02-06 IE IE41890A patent/IE65814B1/en not_active IP Right Cessation
- 1990-02-09 MY MYPI90000213A patent/MY111737A/en unknown
- 1990-02-09 PH PH40033A patent/PH26787A/en unknown
1994
- 1994-08-30 LV LVP-94-169A patent/LV10577B/en unknown
1996
- 1996-03-21 HK HK52196A patent/HK52196A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69003207D1 (de)	1993-10-14
HUT54890A (en)	1991-04-29
DE69003207T2 (de)	1994-02-03
CY1909A (en)	1990-02-02
PH26787A (en)	1992-10-13
AU5038190A (en)	1990-09-05
KR910700048A (ko)	1991-03-13
ATE94063T1 (de)	1993-09-15
HK52196A (en)	1996-03-29
HU205253B (en)	1992-04-28
JP2694361B2 (ja)	1997-12-24
ES2058892T3 (es)	1994-11-01
JPH02209809A (ja)	1990-08-21
KR0140236B1 (ko)	1998-06-01
EP0414847B1 (de)	1993-09-08
EP0414847A1 (de)	1991-03-06
US5093342A (en)	1992-03-03
IE900418L (en)	1990-08-09
WO1990009175A1 (en)	1990-08-23
HU901539D0 (en)	1991-02-28
IE65814B1 (en)	1995-11-15
MY111737A (en)	2000-12-30
CA2025668C (en)	1998-09-15
CA2025668A1 (en)	1990-08-10
LV10577A (lv)	1995-04-20
AU626641B2 (en)	1992-08-06
IL93263A0 (en)	1990-11-29
DK0414847T3 (da)	1993-12-13

Publication	Publication Date	Title
AU626641B2 (en)	1992-08-06	Use of omeprazole as an antimicrobial agent
EP0382489B1 (de)	1994-11-17	Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel
EP0585722A1 (de)	1994-03-09	Benzimidazolverbindungen als Antibiotika gegen Campylobacter pylon
JP3593357B2 (ja)	2004-11-24	抗菌剤
PT655249E (pt)	2001-08-30	Moenomicina como medicamento para o tratamento de ulceras gastricas
JPH06500547A (ja)	1994-01-20	ピリジルメチルスルフィニル―１ｈ―ベンゾイミダゾール誘導体のヘリコバクターにより起こされる病気の治療のための使用
AU665043B2 (en)	1995-12-14	Substituted benzimidazoles, process for their preparation as well as their use
US6271256B1 (en)	2001-08-07	Methods for controlling gram negative bacteria in mammals with bicyclo spiroether compounds
US4312879A (en)	1982-01-26	Clonidine and lofexidine as antidiarrheal agents
JP2798588B2 (ja)	1998-09-17	抗菌剤
JPH0720865B2 (ja)	1995-03-08	抗菌剤
US5780516A (en)	1998-07-14	Material and methods for inhibiting bacterial cell wall biosynthesis
EP0369503B1 (de)	1992-12-23	Methode zur Kontrolle von Pneumocystis carinii
JPH0426631A (ja)	1992-01-29	血管新生抑制剤
JP2952496B2 (ja)	1999-09-27	抗菌剤
JPH03161440A (ja)	1991-07-11	抗菌剤
JPH0977766A (ja)	1997-03-25	４−アミノ−５−ピリミジンカルボン酸誘導体を有効成分とする抗菌剤
EP1057487A1 (de)	2000-12-06	Antimicrobielle zusammenstellungen mit synergistischem effekt, diese enthaltende arzneimittel und heilverfahren für verdauungskrankheiten, deren herstellungsverfahren und damit verbundene zusammenstellungen
JPH0296527A (ja)	1990-04-09	抗潰瘍剤
JPH0338523A (ja)	1991-02-19	抗菌剤
JPWO1999043327A1 (ja)	2002-10-08	相乗作用のある抗菌剤組成物、それを含有する医薬および消化器疾患治療剤、それらの製造法、ならびにそれに関連する製剤
JPH02286617A (ja)	1990-11-26	血管新生阻害剤
JPH0316925B2 (de)	1991-03-06